https://www.oncobites.tv/vnl/%C2%BFqu%C3%A9-hay-de-nuevo-en-el-tratamiento-intensivo-y-no-intensivo-de-la-lma%3F 2026-04-13 https://www.oncobites.tv/vnl/curaci%C3%B3n-en-lmc%3A-un-objetivo-cada-vez-m%C3%A1s-cercano 2026-04-13 https://www.oncobites.tv/vnl/el-gran-dilema-del-mieloma-smoldering%3A-%C2%BFcu%C3%A1ndo-tratar%2C-cu%C3%A1ndo-observar-y-c%C3%B3mo-elegir-la-terapia%3F 2026-04-13 https://www.oncobites.tv/vnl/evidencia-cient%C3%ADfica-sobre-la-estrategia-%C3%B3ptima-de-terapia-puente-antes-del-tratamiento-con-car-t-en-pacientes-con-leucemia-linfobl%C3%A1stica-aguda 2026-04-13 https://www.oncobites.tv/vnl/m%C3%A1s-all%C3%A1-de-la-quimioterapia-en-el-linfoma-folicular-reca%C3%ADdo%2Frefractario 2026-04-13 https://www.oncobites.tv/vnl/philadelphia-positiva%3A-%C2%BFsigue-siendo-imprescindible-el-trasplante%3F 2026-04-13 https://www.oncobites.tv/vnl/an%C3%A1lisis-actualizado-en-el-abordaje-de-la-leucemia-linfoc%C3%ADtica-cr%C3%B3nica 2026-04-13 https://www.oncobites.tv/vnl/terapias-dirigidas-en-linfoma-b-de-c%C3%A9lulas-grandes-revisi%C3%B3n-actualizada 2026-04-13 https://www.oncobites.tv/vnl/criterios-clave-para-elegir-entre-car-t-y-biespec%C3%ADficos-en-mieloma-m%C3%BAltiple-en-reca%C3%ADda 2026-04-13 https://www.oncobites.tv/vnl/estrategias-de-tratamiento-para-manejo-de-reca%C3%ADdas-en-lla 2026-04-13 https://www.oncobites.tv/vnl/opciones-terap%C3%A9uticas-frente-a-una-leucemia-mieloide-aguda-refractaria 2026-04-13 https://www.oncobites.tv/vnl/resistencia-no-es-el-final%2C-nuevos-blancos-en-lmc 2026-04-13 https://www.oncobites.tv/vnl/terapia-cart-en-lla%3A-%C2%BFqu%C3%A9-hemos-aprendido-y-hacia-d%C3%B3nde-vamos%3F 2026-04-13 https://www.oncobites.tv/vnl/leucemia-linfoc%C3%ADtica-cr%C3%B3nica%3A-claves-para-elegir-la-1l-de-tratamiento 2026-04-13 https://www.oncobites.tv/vnl/los-anticuerpos-biespecificos-y-su-rol-en-pacientes-triple-expuestos 2026-04-13 https://www.oncobites.tv/vnl/opciones-de-inmunoterapia-para-linfoma-b-de-c%C3%A9lulas-grandes-hoy 2026-04-13